SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

DRV is a hot topic after news of its collaboration with Synthetix to build derivatives on Ethereum, with the community keenly discussing potential buybacks, resilient chart performance, and anticipating its next leg upward.

"What's Updog?" is a Community Led token.

UpDog

UPDOG CRYPTO is trending, fueled by its dedicated community's persistent engagement with the "What's UpDog?" meme. Discussions actively revolve around accumulating the token, particularly during perceived dips, as the community celebrates its long-standing presence within the Solana ecosystem.

BlockDAG

BlockDAG ($BDAG) is trending due to widespread community frustration and accusations of a potential "scam" following significant issues with coin claiming and transfers after its prolonged presale. Investors are actively discussing disappearing coins, technical errors preventing access to funds, and the validity of multiple token listings, leading to intense debate over the project's legitimacy despite some optimistic long-term holders.

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

SIGA Technologies Inc

SIGA Technologies is trending following a recently declared special cash dividend and widespread anticipation for a new, large BARDA contract renewal to supply its smallpox antiviral, TPOXX, to the U.S. national stockpile. The community is also actively discussing rising global mpox cases and the ongoing debate surrounding TPOXX's efficacy for mpox in human trials.

Coda Octopus Group, Inc. engages in the developing, manufacturing, and marketing of subsea products. The firm operates through the following segments: Marine Technology Business (Products), Acoustics Sensors and Materials Business (PAL), and Defense Engineering Services Business. The Marine Technology Business segment develops solutions for subsea and underwater markets. The Acoustics Sensors and Materials Business segment engages in the provision of a comprehensive range of products and solutions, with a primary focus on medical imaging and Non-Destructive Testing. The Defense Engineering Services Business segment engages in defense contractors and designs, engineers, manufactures and supplies proprietary sub-assemblies for incorporation into broader mission critical defense systems. It also operates through the Americas, Europe, Australia or Asia, and Middle East or Africa geographical segments. The company was founded in 1994 and is headquartered in Orlando, FL.

Coda Octopus Group Inc.

Coda Octopus Group is trending as investors anticipate significant defense contract wins for its advanced underwater sonar and Diver Augmented Vision Display (DAVD) systems, especially amid rising global maritime security needs. Community discussions highlight strong institutional buying and recent positive financial reports, positioning CODA as a potential multi-bagger in the defense technology sector.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending amid recent ecosystem development news, including upgrades to its App Studio and a partnership with CiDi Games for Web3 gaming integration. This positive momentum is balanced by ongoing community discussions and frustrations regarding unverified token balances, KYC issues, and limited availability on major crypto exchanges.

BlackRock Asset Management Canada Ltd - BlackRock Canada iShares S&P/TSX Capped Energy Index ETF

Fueled by escalating geopolitical tensions and a strong rally in commodity prices, the Canadian energy sector is experiencing significant bullish momentum, leading the community to highlight its strategic importance and robust performance as a key market leader.

Invesco Capital Management LLC - PowerShares UltraShort Lehman 20+ Year Treasury ProShares 2x Shares

ProShares UltraShort 20+ Year Treasury ETF

The ProShares UltraShort 20+ Year Treasury ETF is trending as escalating concerns over inflation, particularly rising factory and wholesale prices, and recent hawkish Federal Reserve signals indicate a continued upward bias for long-term Treasury yields. The investment community is actively discussing strategies to capitalize on further bond market weakness, positioning for an environment where "bond vigilantes" may continue to push rates higher.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as escalating geopolitical tensions in the Middle East, coupled with President Trump's calls for a significantly increased defense budget and quadrupled weapons production, fuel community anticipation for substantial demand for defense contractors.

ETF Series Solutions Trust - ESS U.S.Global Jets ETF

US Global Jets ETF

JETS is seeing significant discussion as surging oil prices, driven by Middle East supply disruptions, create headwinds for airlines, sparking debate between those shorting the sector and contrarians betting on a travel demand-led rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>OSR Holdings has until Aug. 31, 2026, to maintain a closing share price of at least $1 for ten consecutive business days.</li><li>Unit Vaximm immuno-oncology asset is pursuing a global licensing deal immuno-oncology asset that could include a $30 million upfront payment and $815 million in milestones.</li><li>OSR said that it is progressing with the planned merger of its units, RMC and Woori IO.</li></ul>Shares of OSR Holdings, Inc. (OSRH) surged more than 20% on Thursday after the company announced that it received an additional 180-day extension from Nasdaq to regain compliance with the exchange’s minimum bid price requirement.On a closing basis, <a href="https://stocktwits.com/symbol/OSRH">OSRH stock</a> is on track to record its biggest intra-day gains so far this year.Nasdaq initially notified OSR Holdings on Sept. 9, 2025, that it was not in compliance with the exchange’s $1 minimum bid price rule after its shares had traded below that level from August 25. OSR was given till March 4, 2026, to regain compliance.The company now has until Aug. 31, 2026, to meet the rule by maintaining a closing share price of at least $1 for ten consecutive business days. OSR noted that there is no immediate impact on the listing or trading of its stock.“We view this extension as a clear operational runway for our strategic initiatives to mature and translate into tangible shareholder value. With multiple near-term catalysts advancing, we believe OSR Holdings is well positioned to strengthen its capital markets profile and return to compliance through disciplined execution,” said Tim Smith, Head of Investor Relations.<h2 class="st-heading-2">Vaximm’s Potential Global Licensing Deal Could Fetch $815 Million</h2>Meanwhile, the company said it remains focused on several strategic initiatives. Its unit Vaximm is working toward a potential global licensing deal for its immuno-oncology asset VXM01, which could include $30 million upfront and up to $815 million in milestone payments.OSR is also progressing with the planned merger of its units, RMC and Woori IO, to build an integrated medical technology and distribution platform, while exploring global partnerships for Woori IO’s non-invasive glucose monitoring technology.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high message volumes.One user expects the stock to reach $10 in the short term.<stembedurl>https://stocktwits.com/JJBurch/message/646695066</stembedurl>The stock has shed around 15% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did OSRH Stock Jump 20% Today?

The company received an additional 180-day extension from Nasdaq to regain compliance after receiving an initial notice on Sept. 9, 2025.

Equity

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch

Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical...

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform

Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform Vaximm Appoints Sbastien Wieckowski, PhD, as Chief Scientific Officer to...

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones

Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones Vaximm, an OSR Company, Receives Binding Term...

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings

Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings Woori IO Shareholders Approve Share Exchange to Become Wholly-Owned Subsidiary of OSR Holdings PR...

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months

Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period...

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025

OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 OSR Holdings to Present at the Emerging Growth Conference on December 10, 2025 PR Newswire BELLEVUE, Wash., Dec. 1, 2025...

Cancer Immunotherapy Microcap Soars on Possible Major Licensing Deal

As pharmaceutical giants increasingly look outside their walls for breakthrough innovations, the licensing model has become the preferred pathway for bringing next-generation therapies to market. Biotech companies with promising platforms are commanding substantial upfront payments and milestone structures that can exceed $800 million, reflecting the pharmaceutical industry's appetite for differentiated assets that address significant unmet medical needs in oncology.Shares of OSR Holdings, Inc. (<a href="https://www.allpennystocks.com/stockquote/osrh" target="_blank">NASDAQ: OSRH</a>) are surging Friday after the company announced that its subsidiary Vaximm AG has entered a non-binding term sheet with BCM Europe AG for a potential exclusive global licensing agreement covering VXM01, Vaximm's first-in-class oral cancer immunotherapy platform.The proposed deal structure outlines significant financial terms that underscore the asset's commercial potential. Vaximm would receive a $20 million upfront payment upon execution of a definitive agreement, followed by up to $815 million in clinical, regulatory, and commercial milestone payments as the program advances through development and commercialization. Additionally, Vaximm would receive a pass-through of commercial royalties that BCME may collect from any future pharmaceutical partner, structured with a defined delta-recovery mechanism that allows BCME to recoup milestone differentials before royalty sharing commences.The term sheet establishes a six-month exclusivity period during which both parties will work toward finalizing a definitive licensing agreement, subject to customary due diligence and board approvals. Under the contemplated framework, BCME would function as a strategic financial intermediary, providing capital to fund the partnering and development activities necessary to secure a global out-license with a major pharmaceutical company. This approach mirrors structured financing models deployed by specialized life sciences investors including Royalty Pharma, Blackstone Life Sciences, and RTW Investments.According to Andreas Niethammer, incoming CEO of Vaximm AG, the term sheet represents an important milestone for advancing VXM01's development and global commercialization while allowing Vaximm to retain full ownership of its intellectual property. The structure enables the company to continue its mission of delivering innovative immunotherapies to patients worldwide with reduced dilution risk.Tim Smith, Head of Investor Relations at OSR Holdings, emphasized that Vaximm's oral T-cell platform represents a genuinely innovative approach in oncology with potential to transform cancer treatment. The exclusivity period with BCME reflects shared commitment to maximizing the global opportunity for VXM01, positioning the asset for a major pharmaceutical partnership that could unlock its full commercial potential.The term sheet also incorporates an optional blockchain-based royalty participation mechanism utilizing "TAC" tokens as an on-chain representation of future royalty revenue streams. Should Vaximm elect to draw development capital from the BCM Royalty Fund, a portion of VXM01 commercial royalties could be allocated to TAC token holders. If this option is not exercised, royalties would flow exclusively through the BCME pass-through structure.Vaximm's VXM01 platform employs a proprietary oral T-cell vaccination approach using live, attenuated bacterial vectors to deliver tumor-associated antigens and induce robust cellular immune responses. The lead candidate targets VEGFR-2 and has demonstrated clinical activity and safety across multiple cancer indications. BCME, a Switzerland-based life sciences investment entity, is currently OSR Holdings' largest shareholder.Shares of OSRH are up 25.8% at $0.57 in Friday afternoon trading. Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.View <a href='https://www.allpennystocks.com/specialreportsUS/4014/cancer-immunotherapy-microcap-soars-on-possible-major-licensing-deal'>more of this article</a> on AllPennyStocks.com.About AllPennyStocks.com Media, Inc.:
Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.
Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.
AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.
Contact:
AllPennyStocks.com Media, Inc.
Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a>
Phone: (800) 558-4560 Ext: 101

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones

Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe...

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion

OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion OSR Holdings Appoints Scientific Co-Founder...

OSR Holdings, Inc. operates as a global healthcare company. The firm engages in developing oral immunotherapies for cancer treatment, design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention of medical devices and systems distribution in Korea. Its products are offered through its subsidiaries. The company was founded on February 25, 2020 and is headquartered in Bellevue, WA.

OSRH
OSR Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest OSRH News

OSRHOSR Holdings Inc